Loading...
Market
Phase 4 studies for injectable Leqembi initiated within 6 months post-approval?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries or company announcements
Story
Eisai and Biogen Submit BLA for Fast Track Injectable Alzheimer’s Drug Leqembi via Autoinjector
May 15, 2024, 11:57 AM
Eisai and Biogen have initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a subcutaneous version of their Alzheimer's drug, Leqembi. This new formulation aims to provide patients with an injectable option via an autoinjector, transitioning from the current infusion method to weekly injections. The submission is under the Fast Track status, which is intended to expedite the review process for drugs that address unmet medical needs. The rolling application was previously delayed by the FDA on procedural grounds.
View original story
Similar markets
Applications in Europe • 25%
Applications in Asia • 25%
Applications in South America • 25%
No applications • 25%
Significantly better than existing treatments • 25%
Marginally better than existing treatments • 25%
Equivalent to existing treatments • 25%
Underperforms existing treatments • 25%
Significant stock price increase (>15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (<5%) • 25%
Stock price decrease • 25%
Donanemab surpasses Leqembi in market share • 33%
Donanemab equals Leqembi in market share • 33%
Leqembi remains ahead in market share • 33%
Aduhelm • 25%
Leqembi • 25%
Lecanemab • 25%
Other • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
